By now, a host of second-generation PSMA-specific antibodies have been prepared and engineered to small antibody fragments, humanized antibodies, radio-labeled derivatives, toxin fusions or bispecific molecules aimed at PCa imaging, diagnosis and therapy (20–24). This evidence concerns the gene FOLH1 and posterior cortical atrophy.